- Details
- Nonna Shakhnazaryan discusses a phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting CD46, in combination with enzalutamide for metastatic castration-resistant prostate cancer. The study establishes the maximally tolerated dose and shows promising results, with 71% of patients experiencing PSA declines, including some who previously progressed on enzalutamide. The med...
|
- Details
- Ashish Kamat interviews Shilpa Gupta about the best of ASCO 2024 in advanced bladder cancer. Dr. Gupta discusses three abstracts: the CheckMate-901 trial's analysis of complete responders to Nivolumab plus gemcitabine-cisplatin in lymph node-only metastatic urothelial cancer; patient-reported outcomes from the EV-302 trial comparing enfortumab vedotin plus pembrolizumab to platinum chemotherapy; a...
|
- Details
- Ashish Kamat interviews Omar Alhalabi about research on small cell neuroendocrine carcinoma of the urinary tract. Dr. Alhalabi discusses the study's findings on prognostic factors for relapse in surgically resected cases. The research reveals that neoadjuvant chemotherapy benefits patients, while the persistence of small cell carcinoma at surgery is associated with a high risk of relapse. The stud...
|
- Details
- Alicia Morgans interviews Karim Fizazi about the updated survival and quality of life data from the PSMAfore trial. The study compares lutetium PSMA to second-line AR pathway inhibitors in metastatic castration-resistant prostate cancer patients who have progressed after one AR pathway inhibitor. Dr. Fizazi discusses the trial's findings, highlighting a significant improvement in radiographic prog...
|
- Details
- Zach Klaassen interviews Karen Hoffman about the PROSTATE-IQ trial, which aims to reduce the burden of androgen deprivation therapy (ADT) in men receiving salvage radiotherapy for prostate cancer. The trial incorporates the ArteraAI Prostate Test to stratify patients and explores alternative treatment strategies, including the use of apalutamide. Dr. Hoffman explains that the study focuses on impr...
|
- Details
- Zach Klaassen welcomes Vitaly Margulis to discuss the ENLIGHTED trial, a phase three study addressing low-grade upper tract urothelial carcinoma. Dr. Margulis explains the necessity of the trial by highlighting the common over-treatment of this cancer type due to the limited and challenging endoscopic management options available. The trial focuses on Vascular Targeted Photodynamic therapy (VTP),...
|
- Details
- Zach Klaassen engages with Talal El Zarif and Karl Semaan to discuss the results of the KEYNOTE-564 trial on adjuvant immunotherapy for renal cell carcinoma (RCC). The conversation emphasizes the landmark approval of pembrolizumab as adjuvant therapy in early-stage RCC, highlighting a significant shift in treatment paradigms where adjuvant systemic therapy had been absent for over fifty years. Drs...
|
- Details
- Rashid Sayyid converses with Dr. Neil Fleshner about the outcomes of the MAST trial, which examined the effects of metformin on patients under active surveillance for prostate cancer. Despite promising preclinical evidence suggesting metformin's potential benefits against prostate cancer, the trial results were unexpectedly negative, showing no significant advantage of metformin in preventing canc...
|
- Details
- Bruce Montgomery discusses the pivotal role of germline testing in cancer predisposition, particularly within the Million Veterans Program. Focusing on prostate cancer, Dr. Montgomery explains that germline testing, which examines inherited DNA, can identify individuals with genetic predispositions to various cancers, including prostate, breast, ovarian, and pancreatic. This testing is crucial for...
|
- Details
- Veda Giri discusses her roles as director of the Cancer Genetics and Prevention Program and the Early-Onset Cancer Program at Yale Cancer Center, highlighting her path through medical school, where her interest in genetics and patient care deepened. Her career was significantly shaped by mentors and opportunities that arose during her residency and fellowships, emphasizing the importance of mentor...
|